Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

Category	Detail
Condition	COVID-19 vaccination in cancer patients
Key Mechanisms	mRNA vaccines elicit humoral and cellular immune responses, targeting the SARS-CoV-2 spike glycoprotein.
Target Population	Patients with cancer, including those receiving systemic therapy and those in remission.
Care Setting	Prospective, phase IV clinical trial.

All patients developed detectable anti-Spike antibodies, with variability based on cancer type and treatment.
Booster doses significantly increased antibody titers, especially in patients in remission.
Prior SARS-CoV-2 infection and number of vaccine doses correlated with better immune responses.
SARS-CoV-2 infection occurred in 16% of the cohort, with infrequent severe cases.
Immunophenotyping confirmed expansion of memory T and B lymphocyte subpopulations post-vaccination.

Consider booster vaccination strategies for patients with cancer, particularly those receiving cytotoxic therapies.

Monitor antibody titers and immune responses longitudinally in cancer patients post-vaccination.

Patients with hematologic malignancies and those receiving chemotherapy may have lower antibody responses.

Patients with cancer, including those on systemic therapy and in remission.

Tailored vaccination approaches may enhance immune responses in immunocompromised populations.

Utilize booster doses to enhance immune responses in cancer patients.
Assess individual patient factors such as prior infection and treatment type when planning vaccination.

Clinical Scorecard: Sustained Immune Reactions to mRNA SARS-CoV-2 Vaccination in Cancer Patients